<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02481440</url>
  </required_header>
  <id_info>
    <org_study_id>hUC-MSC-SCI</org_study_id>
    <nct_id>NCT02481440</nct_id>
  </id_info>
  <brief_title>Repeated Subarachnoid Administrations of hUC-MSCs in Treating SCI</brief_title>
  <official_title>Repeated Subarachnoid Administrations of Human Umbilical Cord Mesenchymal Stem Cells in Treating Spinal Cord Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Limin Rong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of repeated intrathecal
      administrations of allogeneic human umbilical cord mesenchymal stem cells for the treatment
      of spinal cord injury.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Spinal cord injury (SCI) is a devastating disease and often leads to lifelong disability,
      muscle spasm, sensory deficits, autonomic disturbances, as well as bowel and bladder
      incontinence, all of which can cause tremendous troubles to patients but are lack of any
      effective treatment up to now. SCI is not only a severe healthy problem but also a great
      social burden. To the best of our knowledge, cell therapy seems to be a promising alternative
      for the treatment of SCI due to numerous advantages. However, cytotherapy is still in its
      infancy since there are many disparities and uncertainties regarding subject selection,
      cellular type, transplantation timing, administration dose and deliver route in clinical
      trial protocols. Hence, a standardized well-designed clinical study is urgently required for
      the safe and effective treatment of SCI.

      In this study, complete or incomplete cervical, thoracic, and thoracolumbar SCI subjects were
      recruited to join in a prospective, single-center, single-arm clinical trial. Intervention is
      four times of subarachnoid administration of allogeneic hUC-MSCs. During the intervention and
      follow-up periods of this trial, any adverse event was identified rapidly and managed
      properly. The maximum intensity and relationship of any adverse event with hUC-MSCs
      administration were identified.The primary efficacy indicator is American spinal injury
      association (ASIA) total score at the fourth follow-up and SCI Functional Rating Scale of the
      International Association of Neurorestoratology (IANR-SCIFRS) total score at the fourth
      follow-up. Secondary efficacy indicators are these two indicators at the remaining time
      points, scores of pin prick, light touch, motor and sphincter, muscle spasticity and spasm,
      autonomic system, bladder and bowel functions, residual urine volume. Subgroup analysis of
      primary efficacy indicators was also performed.

      In this trial, informed consent forms that had the approval of the institutional review board
      were obtained from all participants before recruitment. In this clinical study, subarachnoid
      transplantation of hUC-MSCs was performed a total of four times per subject with the delivery
      dose of 1Ã—10E6 cells/kg. After the completion of cytotherapy, subject was regularly followed
      up in the hospital at four time points, determined at 1, 3, 6, and 12 months following the
      final administration of hUC-MSCs. At each time point of administration (the first, second,
      third, and fourth transplantation) and follow-up (the first, second, third, and fourth
      follow-up), safety and efficacy indicators were collected accordingly by two independent
      assessors.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 30, 2018</start_date>
  <completion_date type="Actual">March 31, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>American Spinal Injury Association (ASIA) Total Score at the Fourth Follow-up</measure>
    <time_frame>at 12 months following the final administration of hUC-MSCs</time_frame>
    <description>American Spinal Injury Association (ASIA) form is used to assess ASIA total score (Range: 0-324 scores). The higher scores mean a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SCI Functional Rating Scale of the International Association of Neurorestoratology (IANR-SCIFRS) Total Score at the Fourth Follow-up</measure>
    <time_frame>at 12 months following the final administration of hUC-MSCs</time_frame>
    <description>SCI Functional Rating Scale of the International Association of Neurorestoratology (IANR-SCIFRS) form is used to assess IANR-SCIFRS total score (Range: 0-51 scores). The higher scores mean a better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>American Spinal Injury Association (ASIA) Total Score</measure>
    <time_frame>at first, second, third, and fourth transplantation and 1, 3, 6 months following the final administration of hUC-MSCs</time_frame>
    <description>American Spinal Injury Association (ASIA) form is used to assess ASIA total score (Range: 0-324 scores). The higher scores mean a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SCI Functional Rating Scale of the International Association of Neurorestoratology (IANR-SCIFRS) Total Score</measure>
    <time_frame>at first, second, third, and fourth transplantation and 1, 3, 6 months following the final administration of hUC-MSCs</time_frame>
    <description>SCI Functional Rating Scale of the International Association of Neurorestoratology (IANR-SCIFRS) form is used to assess IANR-SCIFRS total score (Range: 0-51 scores). The higher scores mean a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Standards to Document Remaining Autonomic Function After Spinal Cord Injury (ISAFSCI) Score</measure>
    <time_frame>at first transplantation and 12 months following the final administration of hUC-MSCs</time_frame>
    <description>International Standards to document remaining Autonomic Function after Spinal Cord Injury (ISAFSCI) form is used to assess ISAFSCI score (autonomic nervous function) (Range: 5-32 scores). The higher scores mean a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Penn Scale</measure>
    <time_frame>at first transplantation and 12 months following the final administration of hUC-MSCs</time_frame>
    <description>Penn scale form is used to assess muscle spasm (Range: 0-4 scores). The higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Ashworth Scale</measure>
    <time_frame>at first transplantation and 1, 3, 12 months following the final administration of hUC-MSCs</time_frame>
    <description>Modified Ashworth scale form is used to assess muscle spasticity (Range: 0-16 scores). The higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geffner Scale</measure>
    <time_frame>at first transplantation and 12 months following the final administration of hUC-MSCs</time_frame>
    <description>Geffner scale form is used to assess bladder function (Range: 0-7 scores). The higher scores mean a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurogenic Bowel Dysfunction (NBD) Scale</measure>
    <time_frame>at first transplantation and 12 months following the final administration of hUC-MSCs</time_frame>
    <description>Neurogenic Bowel Dysfunction (NBD) scale form is used to assess bowel function (Range: 0-47 scores). The higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual Urine Volume</measure>
    <time_frame>at first transplantation and 12 months following the final administration of hUC-MSCs</time_frame>
    <description>Ultrasonic examination is used to assess residual urine volume</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Spinal Cord Injuries</condition>
  <arm_group>
    <arm_group_label>hUC-MSC Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Repeated intrathecal administrations of 1x10E6 human umbilical cord mesenchymal stem cells per kg in subjects with spinal cord injury with an interval of one month between each administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>human umbilical cord mesenchymal stem cells (hUC-MSCs)</intervention_name>
    <description>Four times of intrathecal administrations of hUC-MSCs</description>
    <arm_group_label>hUC-MSC Transplantation</arm_group_label>
    <other_name>umbilical cord mesenchymal stem cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. complete or incomplete trauma-induced SCI [American Spinal Injury Association (ASIA)
             Impairment Scale classification: A-D] that happened at least two months before
             recruitment;

          2. aged between 18 and 65 years;

          3. agreed to participate in this study voluntarily and be regularly followed up for 12
             months after the completion of hUC-MSCs administration

        Exclusion Criteria:

          1. ankylosing spondylitis, myelitis, or vascular abnormalities within the spinal cord
             parenchyma;

          2. severe comorbidities, including but not limited to craniocerebral injury, cutaneous
             back infection, psychiatric disease, or cancer;

          3. pregnancy or lactation (for females);

          4. predicted lifespan of less than 12 months following the end of hUC-MSCs
             transplantation;

          5. participation in any other stem cell-related clinical trials that might affect
             accurate neurological evaluations in the present trial;

          6. any medical condition that, in the opinion of investigators, may pose a safety risk to
             any subject in this study, confound safety or efficacy assessments, or interfere with
             study participation

        Rejection Criteria:

          1. misdiagnosis;

          2. use of any medication that may significantly impact the assessment accuracy of stem
             cell engraftment;

          3. absence of any evaluation outcome at any time point during the follow-up period

        Cessation Criteria:

          1. individual wishes of the subjects;

          2. occurrence of any stem cell-associated serious adverse event (SAE) that may aggravate
             neurological dysfunction, or require prolongation of existing hospitalization, or need
             hospital readmission, or impair consciousness, or be life-threatening, or even lead to
             death in any subject;

          3. detection of any major mistake in the present protocol during the implementation of
             this clinical trial;

          4. the national administration agency requires the clinical trial to be halted
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Li Rong, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Third Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 15, 2015</study_first_submitted>
  <study_first_submitted_qc>June 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2015</study_first_posted>
  <results_first_submitted>May 21, 2020</results_first_submitted>
  <results_first_submitted_qc>June 13, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 30, 2020</results_first_posted>
  <last_update_submitted>June 13, 2020</last_update_submitted>
  <last_update_submitted_qc>June 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Third Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Limin Rong</investigator_full_name>
    <investigator_title>Director of Spine Surgery Department</investigator_title>
  </responsible_party>
  <keyword>human umbilical cord mesenchymal stem cells</keyword>
  <keyword>spinal cord injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 1, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/40/NCT02481440/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>hUC-MSC Transplantation</title>
          <description>Four times of intrathecal administrations of 1x10E6 human umbilical cord mesenchymal stem cells per kg in subjects with spinal cord injury with an interval of one month between each administration</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>hUC-MSC Transplantation</title>
          <description>Four times of intrathecal administrations of 1x10E6 human umbilical cord mesenchymal stem cells per kg in subjects with spinal cord injury with an interval of one month between each administration</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.1" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Chronicity of SCI</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.15" spread="59.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>American Spinal Injury Association (ASIA) Total Score at the Fourth Follow-up</title>
        <description>American Spinal Injury Association (ASIA) form is used to assess ASIA total score (Range: 0-324 scores). The higher scores mean a better outcome.</description>
        <time_frame>at 12 months following the final administration of hUC-MSCs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>hUC-MSC Transplantation</title>
            <description>Four times of intrathecal administrations of 1x10E6 human umbilical cord mesenchymal stem cells per kg in subjects with spinal cord injury with an interval of one month between each administration</description>
          </group>
        </group_list>
        <measure>
          <title>American Spinal Injury Association (ASIA) Total Score at the Fourth Follow-up</title>
          <description>American Spinal Injury Association (ASIA) form is used to assess ASIA total score (Range: 0-324 scores). The higher scores mean a better outcome.</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183.88" spread="69.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>SCI Functional Rating Scale of the International Association of Neurorestoratology (IANR-SCIFRS) Total Score at the Fourth Follow-up</title>
        <description>SCI Functional Rating Scale of the International Association of Neurorestoratology (IANR-SCIFRS) form is used to assess IANR-SCIFRS total score (Range: 0-51 scores). The higher scores mean a better outcome.</description>
        <time_frame>at 12 months following the final administration of hUC-MSCs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>hUC-MSC Transplantation</title>
            <description>Four times of intrathecal administrations of 1x10E6 human umbilical cord mesenchymal stem cells per kg in subjects with spinal cord injury with an interval of one month between each administration</description>
          </group>
        </group_list>
        <measure>
          <title>SCI Functional Rating Scale of the International Association of Neurorestoratology (IANR-SCIFRS) Total Score at the Fourth Follow-up</title>
          <description>SCI Functional Rating Scale of the International Association of Neurorestoratology (IANR-SCIFRS) form is used to assess IANR-SCIFRS total score (Range: 0-51 scores). The higher scores mean a better outcome.</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.49" spread="10.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>American Spinal Injury Association (ASIA) Total Score</title>
        <description>American Spinal Injury Association (ASIA) form is used to assess ASIA total score (Range: 0-324 scores). The higher scores mean a better outcome.</description>
        <time_frame>at first, second, third, and fourth transplantation and 1, 3, 6 months following the final administration of hUC-MSCs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>hUC-MSC Transplantation</title>
            <description>Four times of intrathecal administrations of 1x10E6 human umbilical cord mesenchymal stem cells per kg in subjects with spinal cord injury with an interval of one month between each administration</description>
          </group>
        </group_list>
        <measure>
          <title>American Spinal Injury Association (ASIA) Total Score</title>
          <description>American Spinal Injury Association (ASIA) form is used to assess ASIA total score (Range: 0-324 scores). The higher scores mean a better outcome.</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3rd follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182.44" spread="71.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178.39" spread="71.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176.05" spread="71.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4th transplantation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172.00" spread="73.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3rd transplantation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168.41" spread="74.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd transplantation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.80" spread="72.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st transplantation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158.15" spread="70.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SCI Functional Rating Scale of the International Association of Neurorestoratology (IANR-SCIFRS) Total Score</title>
        <description>SCI Functional Rating Scale of the International Association of Neurorestoratology (IANR-SCIFRS) form is used to assess IANR-SCIFRS total score (Range: 0-51 scores). The higher scores mean a better outcome.</description>
        <time_frame>at first, second, third, and fourth transplantation and 1, 3, 6 months following the final administration of hUC-MSCs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>hUC-MSC Transplantation</title>
            <description>Four times of intrathecal administrations of 1x10E6 human umbilical cord mesenchymal stem cells per kg in subjects with spinal cord injury with an interval of one month between each administration</description>
          </group>
        </group_list>
        <measure>
          <title>SCI Functional Rating Scale of the International Association of Neurorestoratology (IANR-SCIFRS) Total Score</title>
          <description>SCI Functional Rating Scale of the International Association of Neurorestoratology (IANR-SCIFRS) form is used to assess IANR-SCIFRS total score (Range: 0-51 scores). The higher scores mean a better outcome.</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3rd follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.93" spread="10.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.44" spread="10.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.56" spread="10.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4th transplantation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.85" spread="10.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3rd transplantation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.05" spread="10.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd transplantation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.71" spread="10.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st transplantation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.54" spread="9.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>International Standards to Document Remaining Autonomic Function After Spinal Cord Injury (ISAFSCI) Score</title>
        <description>International Standards to document remaining Autonomic Function after Spinal Cord Injury (ISAFSCI) form is used to assess ISAFSCI score (autonomic nervous function) (Range: 5-32 scores). The higher scores mean a better outcome.</description>
        <time_frame>at first transplantation and 12 months following the final administration of hUC-MSCs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>hUC-MSC Transplantation</title>
            <description>Four times of intrathecal administrations of 1x10E6 human umbilical cord mesenchymal stem cells per kg in subjects with spinal cord injury with an interval of one month between each administration</description>
          </group>
        </group_list>
        <measure>
          <title>International Standards to Document Remaining Autonomic Function After Spinal Cord Injury (ISAFSCI) Score</title>
          <description>International Standards to document remaining Autonomic Function after Spinal Cord Injury (ISAFSCI) form is used to assess ISAFSCI score (autonomic nervous function) (Range: 5-32 scores). The higher scores mean a better outcome.</description>
          <units>score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4th follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="11" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st transplantation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="10" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Penn Scale</title>
        <description>Penn scale form is used to assess muscle spasm (Range: 0-4 scores). The higher scores mean a worse outcome.</description>
        <time_frame>at first transplantation and 12 months following the final administration of hUC-MSCs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>hUC-MSC Transplantation</title>
            <description>Four times of intrathecal administrations of 1x10E6 human umbilical cord mesenchymal stem cells per kg in subjects with spinal cord injury with an interval of one month between each administration</description>
          </group>
        </group_list>
        <measure>
          <title>Penn Scale</title>
          <description>Penn scale form is used to assess muscle spasm (Range: 0-4 scores). The higher scores mean a worse outcome.</description>
          <units>score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4th follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st transplantation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Ashworth Scale</title>
        <description>Modified Ashworth scale form is used to assess muscle spasticity (Range: 0-16 scores). The higher scores mean a worse outcome.</description>
        <time_frame>at first transplantation and 1, 3, 12 months following the final administration of hUC-MSCs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>hUC-MSC Transplantation</title>
            <description>Four times of intrathecal administrations of 1x10E6 human umbilical cord mesenchymal stem cells per kg in subjects with spinal cord injury with an interval of one month between each administration</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Ashworth Scale</title>
          <description>Modified Ashworth scale form is used to assess muscle spasticity (Range: 0-16 scores). The higher scores mean a worse outcome.</description>
          <units>score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4th follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="0" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st transplantation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geffner Scale</title>
        <description>Geffner scale form is used to assess bladder function (Range: 0-7 scores). The higher scores mean a better outcome.</description>
        <time_frame>at first transplantation and 12 months following the final administration of hUC-MSCs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>hUC-MSC Transplantation</title>
            <description>Four times of intrathecal administrations of 1x10E6 human umbilical cord mesenchymal stem cells per kg in subjects with spinal cord injury with an interval of one month between each administration</description>
          </group>
        </group_list>
        <measure>
          <title>Geffner Scale</title>
          <description>Geffner scale form is used to assess bladder function (Range: 0-7 scores). The higher scores mean a better outcome.</description>
          <units>score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4th follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st transplantation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurogenic Bowel Dysfunction (NBD) Scale</title>
        <description>Neurogenic Bowel Dysfunction (NBD) scale form is used to assess bowel function (Range: 0-47 scores). The higher scores mean a worse outcome.</description>
        <time_frame>at first transplantation and 12 months following the final administration of hUC-MSCs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>hUC-MSC Transplantation</title>
            <description>Four times of intrathecal administrations of 1x10E6 human umbilical cord mesenchymal stem cells per kg in subjects with spinal cord injury with an interval of one month between each administration</description>
          </group>
        </group_list>
        <measure>
          <title>Neurogenic Bowel Dysfunction (NBD) Scale</title>
          <description>Neurogenic Bowel Dysfunction (NBD) scale form is used to assess bowel function (Range: 0-47 scores). The higher scores mean a worse outcome.</description>
          <units>score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4th follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st transplantation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="2" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Residual Urine Volume</title>
        <description>Ultrasonic examination is used to assess residual urine volume</description>
        <time_frame>at first transplantation and 12 months following the final administration of hUC-MSCs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>hUC-MSC Transplantation</title>
            <description>Four times of intrathecal administrations of 1x10E6 human umbilical cord mesenchymal stem cells per kg in subjects with spinal cord injury with an interval of one month between each administration</description>
          </group>
        </group_list>
        <measure>
          <title>Residual Urine Volume</title>
          <description>Ultrasonic examination is used to assess residual urine volume</description>
          <units>ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4th follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.90" lower_limit="8.83" upper_limit="88.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st transplantation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.65" lower_limit="31.58" upper_limit="144.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the intervention and follow-up periods of this trial, up to 16 months, any AE was identified and collected.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>hUC-MSC Transplantation</title>
          <description>Four times of intrathecal administrations of 1x10E6 human umbilical cord mesenchymal stem cells per kg in subjects with spinal cord injury with an interval of one month between each administration</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="54" subjects_affected="25" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>transient increase of muscle tension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Li-Min Rong M.D., Director of Clinical Trials</name_or_title>
      <organization>The Third Affiliated Hospital of Sun Yat-sen University</organization>
      <phone>862085252900</phone>
      <email>ronglimin@21cn.com, ronglm@mail.sysu.edu.cn</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

